TauroLock™-HEP500

• hemodialysis

• 1.35 % taurolidine: broad antimicrobial activity against bacteria and fungi without generating resistance
• 4 % citrate: anticoagulant to maintain patency
• 500 IU/ml heparin: anticoagulant to maintain patency 

• prevention of biofilm
• prevention of occlusion
• prevention of infection

• single dose: 5 ml ampoules (10 per box)
• multiple dose: 10 ml vials (100 per box)
• store between 15 and 30 °C (do not freeze) 

Clinical study 2021

“Use of [TauroLock™-HEP500] for temporary hemodialysis catheters was associated with lower levels of inflammation markers and lower incidence of CRBSI and better catheter performance.” 

Ezzat et al. J Vasc Access 2023. DOI: 10.1177/11297298211023295 

Clinical study 2021

“Removal of CVC [central-venous catheter] due to infection or catheter malfunction occurred less often with taurolidine-based lock solutions [TauroLock™ and TauroLock™-HEP500].”  

Van Roeden et al. BMC Nephrology 2021. DOI: 10.1186/s12882-021-02519-3 

Clinical study 2018

“... use of taurolidine-based catheter lock solutions containing heparin [TauroLock™-HEP500] and urokinase [TauroLock™-U25.000] significantly reduced complications related to tunneled hemodialysis catheters when compared to four percent citrate solution and was overall more cost-efficient.” 

Winnicki et al. Kidney Int 2018. DOI: 10.1016/j.kint.2017.06.026

Clinical study 2012

“[TauroLock™-HEP500] reduces the need for thrombolysis without increasing bacteremia and may achieve patency comparable to heparin 5000 U/ml.” 

Solomon et al. Semin Dial 2012. DOI: 10.1111/j.1525-139X.2011.00951.x